The Babak Lab shared on LinkedIn:
“Can cancer cells undergo cuproptosis without FDX1?
Cuproptosis is a copper-dependent form of cell death associated with mitochondrial protein aggregation. Until now, its best-characterized mechanism involved FDX1, a mitochondrial enzyme required for elesclomol-induced cuproptosis.
A new study published in Molecular Cancer identifies a second, FDX1-independent pathway, triggered by the copper-binding compound neocuproine.
Key Insights
- Elesclomol induces canonical, FDX1-dependent cuproptosis, while neocuproine triggers a distinct FDX1-independent pathway.
- Both compounds cause early oligomerization of lipoylated DLAT, followed by loss of iron–sulfur proteins, impaired respiration and mitochondrial dysfunction.
- Depleting the copper chaperone ATOX1 partially protected cells from neocuproine, but not elesclomol, suggesting different copper-handling mechanisms.
- Analysis of more than 430 cancer cell lines linked sensitivity to both compounds with oxidative phosphorylation (OXPHOS). Neocuproine sensitivity was additionally associated with a mesenchymal/EMT-like state.
- CRISPRa screening identified proteasomal and lysosomal pathways involved in cellular adaptation to neocuproine. Inhibiting these pathways increased its cytotoxicity.
Conclusion
FDX1 is not required for every form of copper-dependent cell death. Neocuproine and elesclomol act through different copper-handling mechanisms but ultimately disrupt the same mitochondrial machinery.”
Title: FDX1-independent non-canonical cuproptosis establishes a parallel mitochondria-centric death program
Authors: Jana J. Bachmann, Maria Grazia Molvetti, Andelija Trajkovic, Veronika Haunerdinger, Ana Kitanovic, Tobias Schöberl, Maximilian Dünnebacke, Alexandre Leytens, Patrick Turko, Dimitra Stylios, Hannah Zillikens, Thomas Look, Deborah Villano, Flavia Tellenbach, Prachi Shukla, Mauro Esposito, Detlef Günther, Tatjana Kleele, Paola Picotti, Jörn Dengjel, Andreas Dzung, Mitchell P. Levesque, Ossia M. Eichhoff
You may also be interested in: How Radiation Therapy Kills Cancer Cells: When Does It Start Working?
